Yikon Genomics

About:

This company is a Genetic Tests To Support Family Planning Stages of Life.

Website: http://www.yikongenomics.com

Twitter/X: yikon_genomics

Top Investors: Oriza Holdings, Guangzhou Yuexiu Industrial Investment Fund, Sinopharm Capital, General Technology Venture Capital, Zhongjin Qide

Description:

Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.

Total Funding Amount:

$69.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minhang, Shanghai, China

Founded Date:

2012-01-01

Contact Email:

nfo(AT)yikongenomics.com

Founders:

Sunney Xie

Number of Employees:

51-100

Last Funding Date:

2021-05-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai